Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing partner, Duality Biologics (Suzhou) Co., Ltd. This new deal grants BioNTech global development, manufacturing, and commercialization rights to the antibody drug conjugate (ADC) DB-1305, excluding Greater China, which includes China mainland, Hong Kong, and Macau. The financial details of the agreement have not been disclosed.
DB-1305: A Third Generation Trop2 ADC with Promising Preclinical and Clinical Results
DB-1305, a third generation Trop2 ADC based on Duality’s DITAC platform, has demonstrated strong anti-tumor activity in preclinical tumor models and significant clinical efficacy in solid tumors, including non-small cell lung cancer. This expansion of the partnership builds upon the success of the companies’ previous collaboration.
Previous Licensing Deal and Global Expansion
In April of this year, the two firms had already struck a USD 1.67 billion licensing deal, which allowed BioNTech to develop, manufacture, and commercialize two other ADCs, DB-1303 and DB-1311, around the world, with the exception of China mainland, Hong Kong, and Taiwan. The latest agreement further solidifies the strategic partnership between BioNTech and Duality Biologics, aiming to leverage the potential of Duality’s innovative ADC platform on a global scale.-Fineline Info & Tech
